{"name":"Cyclo Therapeutics, Inc.","slug":"cyclo-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hydroxypropyl-beta-cyclodextrin","genericName":"Hydroxypropyl-beta-cyclodextrin","slug":"hydroxypropyl-beta-cyclodextrin","indication":"Niemann-Pick disease type C (NPC)","status":"phase_3"}]}],"pipeline":[{"name":"Hydroxypropyl-beta-cyclodextrin","genericName":"Hydroxypropyl-beta-cyclodextrin","slug":"hydroxypropyl-beta-cyclodextrin","phase":"phase_3","mechanism":"Hydroxypropyl-beta-cyclodextrin is a solubilizing excipient that forms inclusion complexes with lipophilic drugs to improve their bioavailability and enable intravenous delivery.","indications":["Niemann-Pick disease type C (NPC)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxONm1IZEZEaUh3dWZMNUdocWp1R3Fkc29TZFZsY25lZ3Uyb0R4LWZJa05VTUtncEJ0WjNERFR2VTVHNHN4YlZBVlV6VUpja1puX012UkZMSUo0OXBFQW5iYWl4NkxDdG5Lckt4VHBlSVB1UWZ1ZzV4VEJDdjQwTVluWHBsN3pwYjVsT0N0QnBmVm50Z3dh?oc=5","date":"2026-02-20","type":"pipeline","source":"Insightace Analytic","summary":"Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2035 - Insightace Analytic","headline":"Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2035","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-19","type":"regulatory","source":"Express Pharma","summary":"Dr Reddy’s Laboratories acquires Progynova and Cyclo-Progynova trademarks from Mercury Pharma for India - Express Pharma","headline":"Dr Reddy’s Laboratories acquires Progynova and Cyclo-Progynova trademarks from Mercury Pharma for India","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPbTQ4dFNtN3ZWMHZHY1NwMmgzbVZvVzF0VElQNWVWWXVHQ1BjTXIxTmQ4VWY4RGdfVlFVYkU0LVBPbHZJQThMQmRHRGFYc19yYXZOeFJVSjh2UFNoR2hfT0tHZmZYdmdpVDJlOWtnQklZSERqdWxidWtvVjJCLWQyMVladEh4b0hsZ0lXZGRkWXFsc1FLU1hjWkdDdmx3WmNSQ0FfT1FGcmIxejI3Rnk3LWpCbm8yNS0xQmUtVFRsajhtTHdrWkZ6S3gwNTNxd1cxTkE3RWZnS2t6V3FLY2FUN2JQbGRrVWlMY1kzRkdRcUVVMms3WUhPQnhCbkwzeWxsRnFva0oyVEVjdUx6ZTAycFBQakh0dXVSRENRb2hfTjBoNEtUOTZGdGtNem5nemJBaEQ0elRhT245eG9H?oc=5","date":"2026-01-28","type":"trial","source":"GlobeNewswire","summary":"Chronic and Acute Pain Clinical Trial Pipeline Analysis: - GlobeNewswire","headline":"Chronic and Acute Pain Clinical Trial Pipeline Analysis:","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPUTFLRFVXMm11WGVFR2ZLdm1Ba1VWckZ0ckkwdWRhZzdValZkX3paWEpmUEZ0b0x4SVhqU1BrdVgyaDdhV2V4TzkxQkFPd3FRWktfTzlBM1FBWTE4RzJ6QlIyZmMyUVZaZEEya2laZUJScVpaMEdZY3NNV014MHpBYnNxMG0yU3QzSVFYMl9YQ3IzY19kZVBQVG9JTjVVZ19yOUtEbTFpRGFYcFdrN1JDZG54eHA3Q1MwU3NEWm1oeFBlLWhyR29Gc3RIOUJrZk9SV2ZyN3NYWUtPaGZ0SXZCUmNObng0M25oY3U5ZUxmRWtCQklvbEpYTlpuSHRuSHVlVVhzcGdDcEVQMGlTcjI1U0s4SW9DSDQ?oc=5","date":"2025-10-29","type":"regulatory","source":"Quiver Quantitative","summary":"Rafael Holdings, Inc. Reports Continued Progress in Phase 3 Trial of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 and Announces New COO - Quiver Quantitative","headline":"Rafael Holdings, Inc. Reports Continued Progress in Phase 3 Trial of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9ZSWJEUks2VWt2bzVicU1oOEp1RW1tYnZBSTZpMnEzeEo4eGVBUmxjNlU2dlBBNF9wQzc0VVIwcXhORWJwUjNpWTFvM2RFNE1naUxscW8xVDdZQ1BvTkZFQXdfR3JYODl1d1RVY3I5QmlhNE55RGdsZEs3REZSdw?oc=5","date":"2025-10-29","type":"regulatory","source":"Yahoo Finance","summary":"Niemann-Pick Disease Type C Market is Expected to Showcase Significant Growth at a CAGR of 14.8% During the Forecast Period (2025–2034) | DelveInsight - Yahoo Finance","headline":"Niemann-Pick Disease Type C Market is Expected to Showcase Significant Growth at a CAGR of 14.8% During the Forecast Per","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNTzdpM01leFlKVUxOQlpodEhaa2VFbjdvcDNpZ2NSV2xmUENMa1RyUmpTVXl5cUtuZ1c1NlRNYV9jY3hnYmtZaWFRT3oySl9zbTZmbjFXRVNlSVU5aV9IWmxrWTMyOEhBUXUwbWR0dFJWRm9lZHZxZmVLMGF2LVB5cWhwODdadjh6MDA1VGN5V0FiYTNjanVtNVVPUXRselJOZ3JtZnpWaEFQNjJSMjVlV2NWc1VEZw?oc=5","date":"2025-06-11","type":"earnings","source":"Moomoo","summary":"Press Release: Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results - Moomoo","headline":"Press Release: Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE41eDRaTEpMbzBvaHpTY3hDVUQyVGFfNGFPajQ4NVEzVEhOdHNQalh2SXRBanpUUzk5bmF0ZE9EQ1VBMVJXV0tuZWQ5cmNjMC1QcXdj?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"CYTH Stock Price, News & Analysis - Stock Titan","headline":"CYTH Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxPTXZ1dkpBT3paTWo3N3JJRUJzcVJyOGdIZ0tfZ1EtYkJyWk5CckxyVGJCQVJQSUxPblJuenRlNWZNa214ZzNuTVBNRXV5emhUbWx6M0pHVTk3emtEdzlyYmRERXVhbG1tVXpiSHhkeXF4b3M1bS1Ta3ZPVlBVYjBoRmZmbllSS2JzSWhXYUtHVUw1LUpVUGM2SGJndkhoaE05alFDdXhzb0lXdEZiYjB1enJ2aEF6V2ZtcmtUbll3X04zcEVYZnZaT3NmSzB0blBzSk5Cb1NQOFBzU0JkZURCUVMyYlZZR1NzWTBKaDNLbHFWZw?oc=5","date":"2025-03-26","type":"regulatory","source":"GlobeNewswire","summary":"Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals - GlobeNewswire","headline":"Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQQkFGTV9ZblNJU3g5OTEyV2dDNUtvZ2lhZ3VrRkIwRmdLXzVybmdJNFpMWVYyWGRFTXFPb0VaRk8xZUxZeHUwTThYdnIzek80aXh6LXQyOUlORTV2T2Y3TVNhbzFnUWpRUDRVQ1k2OXVWN0FVY3ZCcGt6aUNJZ2E0OE5XTlFET0NRUVJKd1pRR2JDVVREM2wtbm1NX18yQlJjREJ5cjRfZElSNEFBMEZVYUU0a08zQXc3SU1CUjdCOUdva1ZqanoxRC1OWTd1bWVXRzFhamg2TDR5Qmhr?oc=5","date":"2025-03-13","type":"earnings","source":"TradingView","summary":"Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results - TradingView","headline":"Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNZzVTMHNMYjlzY3ZLeU92OUs2ekxvLWRFTUpDMXo1QnQ2RUtnN00xTEJiTmc5VXA1RW93dUNUcXZXb3l6U3MwX2NsakE5bnVLUnZWam4yWkxjY2ZmX1lJeEx0RjlaaDU2SlNaU1VzRnhDamtjZEtBclNsR2o2WmdETjA2aW5OZEdob0RjQ3h0dWdDanlrT2IyRGJ1dDBHemg3ZW9RcGJqY2dmNWNFYy1F?oc=5","date":"2024-08-22","type":"deal","source":"Investing.com India","summary":"Rafael Holdings and Cyclo Therapeutics announce merger By Investing.com - Investing.com India","headline":"Rafael Holdings and Cyclo Therapeutics announce merger By Investing.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQVjdtanZxRTYyN3FmRDNERXBvd3M5b2IwS2FuZUtGaWtnOGI2UUdUYndqcmg2a2VKSW5jV1d3X3dKQnY5UldYOEd1SFFqLXNhVlhJQWdyeGJrM0tVMDdqZlhDME8xZU1DY0w3YkJsckhhaFVrQmw4djhZdnkzRjViYXo5T2prMV9JX2JuTURmMzlnRGE3ek1TeHlnN1JUUF83N3dIeThoX3RpdlhrRUE?oc=5","date":"2023-09-25","type":"pipeline","source":"The Business Journals","summary":"This biotech went public 3 years ago at $14 per share. Here's how its stock cratered to 27 cents - The Business Journals","headline":"This biotech went public 3 years ago at $14 per share. Here's how its stock cratered to 27 cents","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-09-19","type":"regulatory","source":"prnewswire.com","summary":"Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos He","headline":"Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the Market - Azafaro","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}